Dy­nacure se­cures $55M as their Io­n­is-de­vel­oped drug moves in­to clin­ic

A month af­ter dos­ing their first ever pa­tient with their Io­n­is-li­censed tech, Dy­nacure has an­nounced a new round of fund­ing to ad­vance the tri­al.

The French biotech an­nounced €50 mil­lion ($55 mil­lion) in Se­ries C fund­ing, led by Per­cep­tive Ad­vi­sors. Al­though list­ed as a Se­ries C, it is the sec­ond tranche of cash the com­pa­ny has ever an­nounced, af­ter their ini­tial $55 mil­lion raise in 2018. The cash will float Dy­nacure through its Phase I/II tri­al in a class of neu­ro­mus­cu­lar dis­eases known as my­otubu­lar and cen­tronu­clear my­opathies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER